CA2565215C - Method and system to remove soluble tnfr1, tnfr2, and il2 in patients - Google Patents
Method and system to remove soluble tnfr1, tnfr2, and il2 in patients Download PDFInfo
- Publication number
- CA2565215C CA2565215C CA2565215A CA2565215A CA2565215C CA 2565215 C CA2565215 C CA 2565215C CA 2565215 A CA2565215 A CA 2565215A CA 2565215 A CA2565215 A CA 2565215A CA 2565215 C CA2565215 C CA 2565215C
- Authority
- CA
- Canada
- Prior art keywords
- plasma
- patients
- stnfr1
- stnfr2
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title abstract description 91
- 101100425758 Mus musculus Tnfrsf1b gene Proteins 0.000 title 1
- 101150009046 Tnfrsf1a gene Proteins 0.000 title 1
- 210000004369 blood Anatomy 0.000 claims abstract description 38
- 239000008280 blood Substances 0.000 claims abstract description 38
- 239000000463 material Substances 0.000 claims abstract description 17
- 238000009739 binding Methods 0.000 claims description 42
- 102000004127 Cytokines Human genes 0.000 claims description 16
- 108090000695 Cytokines Proteins 0.000 claims description 16
- 239000011159 matrix material Substances 0.000 claims description 12
- 239000012528 membrane Substances 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 8
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims description 6
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 5
- 239000011324 bead Substances 0.000 claims description 5
- 238000000502 dialysis Methods 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims description 4
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims description 4
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims description 4
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 97
- 206010028980 Neoplasm Diseases 0.000 abstract description 64
- 108010002350 Interleukin-2 Proteins 0.000 abstract description 12
- 102000000588 Interleukin-2 Human genes 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 230000009467 reduction Effects 0.000 abstract description 10
- 230000005855 radiation Effects 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 4
- 238000011254 conventional chemotherapy Methods 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 description 72
- 102000005962 receptors Human genes 0.000 description 53
- 108020003175 receptors Proteins 0.000 description 53
- 239000003112 inhibitor Substances 0.000 description 31
- 238000002617 apheresis Methods 0.000 description 16
- 201000011510 cancer Diseases 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 210000000987 immune system Anatomy 0.000 description 11
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000002411 adverse Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 102000003675 cytokine receptors Human genes 0.000 description 7
- 108010057085 cytokine receptors Proteins 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 230000028709 inflammatory response Effects 0.000 description 6
- 238000002616 plasmapheresis Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 238000001179 sorption measurement Methods 0.000 description 6
- 108700020463 BRCA1 Proteins 0.000 description 5
- 102000036365 BRCA1 Human genes 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 239000012503 blood component Substances 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- -1 cisplatinum Chemical compound 0.000 description 5
- 238000002591 computed tomography Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 208000037819 metastatic cancer Diseases 0.000 description 5
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 229920000515 polycarbonate Polymers 0.000 description 5
- 239000004417 polycarbonate Substances 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 206010053567 Coagulopathies Diseases 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 210000001601 blood-air barrier Anatomy 0.000 description 4
- 230000035602 clotting Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 206010045170 Tumour lysis syndrome Diseases 0.000 description 3
- 206010054094 Tumour necrosis Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 229920002492 poly(sulfone) Polymers 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000010380 tumor lysis syndrome Diseases 0.000 description 3
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 206010065390 Inflammatory pain Diseases 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940127090 anticoagulant agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229920001169 thermoplastic Polymers 0.000 description 2
- 239000004416 thermosoftening plastic Substances 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 1
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010091326 Cryoglobulins Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 108091036060 Linker DNA Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010028164 Multiple allergies Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 206010038111 Recurrent cancer Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 208000003837 Second Primary Neoplasms Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 108010091268 alpha-Macroglobulins Proteins 0.000 description 1
- 102000018162 alpha-Macroglobulins Human genes 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000007469 bone scintigraphy Methods 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000012052 concurrent chemoradiation therapy Methods 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002565 electrocardiography Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000011545 laboratory measurement Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000008949 local secretion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229940124583 pain medication Drugs 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000001321 subclavian vein Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3403—Regulation parameters
- A61M1/3406—Physical characteristics of the filtrate, e.g. urea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3482—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate by filtrating the filtrate using another cross-flow filter, e.g. a membrane filter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
- A61M1/3489—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents by biological cells, e.g. bioreactor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3687—Chemical treatment
- A61M1/3689—Chemical treatment by biological cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biodiversity & Conservation Biology (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56674104P | 2004-04-30 | 2004-04-30 | |
| US60/566,741 | 2004-04-30 | ||
| PCT/US2005/015037 WO2005107802A2 (en) | 2004-04-30 | 2005-04-29 | Method and system to remove soluble tnfr1, tnfr2, and il2 in patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2565215A1 CA2565215A1 (en) | 2005-11-17 |
| CA2565215C true CA2565215C (en) | 2014-04-15 |
Family
ID=35320738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2565215A Expired - Fee Related CA2565215C (en) | 2004-04-30 | 2005-04-29 | Method and system to remove soluble tnfr1, tnfr2, and il2 in patients |
Country Status (16)
| Country | Link |
|---|---|
| US (6) | US20050265996A1 (enEXAMPLES) |
| EP (2) | EP1949915B1 (enEXAMPLES) |
| JP (1) | JP2008511340A (enEXAMPLES) |
| CN (1) | CN1980696B (enEXAMPLES) |
| AU (2) | AU2005240082B2 (enEXAMPLES) |
| CA (1) | CA2565215C (enEXAMPLES) |
| CY (1) | CY1113345T1 (enEXAMPLES) |
| DK (1) | DK1949915T3 (enEXAMPLES) |
| ES (1) | ES2393637T3 (enEXAMPLES) |
| IL (2) | IL178845A (enEXAMPLES) |
| IN (1) | IN2009DN07374A (enEXAMPLES) |
| PL (1) | PL1949915T3 (enEXAMPLES) |
| PT (1) | PT1949915E (enEXAMPLES) |
| RU (1) | RU2378016C2 (enEXAMPLES) |
| SI (1) | SI1949915T1 (enEXAMPLES) |
| WO (1) | WO2005107802A2 (enEXAMPLES) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8197430B1 (en) | 1998-05-22 | 2012-06-12 | Biopheresis Technologies, Inc. | Method and system to remove cytokine inhibitor in patients |
| US6620382B1 (en) * | 1998-05-22 | 2003-09-16 | Biopheresis Technologies, Llc. | Method and compositions for treatment of cancers |
| EP1949915B1 (en) * | 2004-04-30 | 2012-08-22 | BioPheresis Technologies, Inc. | Method and system to remove soluble TNFR1, TNFR2, and IL2R in patients |
| EP1781818B1 (en) * | 2004-07-22 | 2017-09-06 | Early Detection, LLC | CANCER AND INFLAMMATION DIAGNOSIS USING ANTI sTNFR ANTIBODIES |
| US7918863B2 (en) | 2005-06-24 | 2011-04-05 | Conceptus, Inc. | Minimally invasive surgical stabilization devices and methods |
| US20100130904A1 (en) * | 2005-07-18 | 2010-05-27 | Trustees Of Boston University | Method to inhibit proliferation and growth of metastases |
| WO2007103572A2 (en) | 2006-03-09 | 2007-09-13 | Aethlon Medical, Inc. | Extracorporeal removal of microvesicular particles |
| US20080269762A1 (en) * | 2007-04-25 | 2008-10-30 | Biomet Manufacturing Corp. | Method and device for repair of cartilage defects |
| MX2010002351A (es) * | 2007-08-31 | 2010-05-27 | Univ Michigan | Dispositivos de citoforesis selectivos y metodos relacionados con los mismos. |
| JP2009178523A (ja) * | 2008-02-01 | 2009-08-13 | Kaneka Corp | 可溶性腫瘍壊死因子受容体の吸着材、吸着方法および吸着装置 |
| WO2009108890A1 (en) | 2008-02-27 | 2009-09-03 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
| US8753690B2 (en) * | 2008-02-27 | 2014-06-17 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
| US8905760B2 (en) * | 2008-11-04 | 2014-12-09 | Duane C. Keller | Methods and systems for progressively treating and controlling oral periopathogens causing systemic inflammations |
| US8758287B2 (en) | 2008-11-12 | 2014-06-24 | Marv Enterprises, LLC | Utilization of stents for the treatment of blood borne carcinomas |
| JP5249737B2 (ja) * | 2008-12-10 | 2013-07-31 | 旭化成メディカル株式会社 | 血液からウイルス及びサイトカインを除去するシステム |
| US8430831B2 (en) | 2009-02-25 | 2013-04-30 | The Invention Science Fund I, Llc | Device, system, and method for controllably reducing inflammatory mediators in a subject |
| US9216386B2 (en) * | 2009-03-17 | 2015-12-22 | Marv Enterprises, LLC | Sequential extracorporeal treatment of bodily fluids |
| CA2772084C (en) | 2009-08-27 | 2016-10-18 | Biomet Biologics, Llc | Implantable device for production of interleukin-1 receptor antagonist |
| US20110052561A1 (en) * | 2009-08-27 | 2011-03-03 | Biomet Biologics,LLC | Osteolysis treatment |
| CA2799227C (en) | 2010-05-14 | 2020-06-16 | Beth Israel Deaconess Medical Center, Inc. | Extracorporeal devices and methods of treating complications of pregnancy |
| EP2977054A1 (en) | 2010-09-03 | 2016-01-27 | Biomet Biologics, LLC | Methods and compositions for delivering interleukin-1 receptor antagonist |
| WO2012051595A1 (en) | 2010-10-15 | 2012-04-19 | Cytopherx, Inc. | Cytopheresic cartridge and use thereof |
| JP2014503187A (ja) | 2010-10-29 | 2014-02-13 | ノクソン ファーマ エージー | 身体からヘプシジンを除去するためのヘプシジン結合核酸の使用 |
| US20130131423A1 (en) * | 2011-04-12 | 2013-05-23 | Tianxin Wang | Methods to detect and treat diseases |
| EP2707055B1 (en) * | 2011-05-09 | 2019-10-23 | The University of Miami | Reducing soluble urokinase receptor in the circulation |
| US9138343B2 (en) | 2011-05-31 | 2015-09-22 | Bayer Healthcare Llc | Tip protector sleeve |
| WO2012163544A1 (en) | 2011-06-01 | 2012-12-06 | Biopheresis Technologies, Inc. | Removal of soluble tumor necrosis factor receptor 2 (stnfr2) |
| US10426356B2 (en) | 2011-07-09 | 2019-10-01 | Gauss Surgical, Inc. | Method for estimating a quantity of a blood component in a fluid receiver and corresponding error |
| US8983167B2 (en) | 2012-05-14 | 2015-03-17 | Gauss Surgical | System and method for estimating a quantity of a blood component in a fluid canister |
| US9652655B2 (en) * | 2011-07-09 | 2017-05-16 | Gauss Surgical, Inc. | System and method for estimating extracorporeal blood volume in a physical sample |
| US9936906B2 (en) | 2012-05-14 | 2018-04-10 | Gauss Surgical, Inc. | System and methods for managing blood loss of a patient |
| US8764695B2 (en) * | 2012-09-28 | 2014-07-01 | Isaac Eliaz | Reduction of galectin-3 levels by plasmapheresis |
| US9549953B2 (en) * | 2011-12-08 | 2017-01-24 | Eliaz Therapeutics, Inc. | Galectin-3 plasmapheresis therapy |
| CA2860831A1 (en) | 2012-01-09 | 2013-07-18 | H. David Humes | Cartridge and method for increasing myocardial function |
| US20150027950A1 (en) * | 2012-03-27 | 2015-01-29 | Marv Enterprises, LLC | Treatment for atherosclerosis |
| WO2013179143A2 (en) | 2012-06-01 | 2013-12-05 | Biopheresis Technologies, Inc. | Sensitization of cancer cells by the removal of soluble tumor necrosis factor receptors |
| US9758806B2 (en) | 2013-03-15 | 2017-09-12 | Biomet Biologics, Llc | Acellular compositions for treating inflammatory disorders |
| US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
| US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
| US9878011B2 (en) | 2013-03-15 | 2018-01-30 | Biomet Biologics, Llc | Treatment of inflammatory respiratory disease using biological solutions |
| US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
| US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
| US9950035B2 (en) | 2013-03-15 | 2018-04-24 | Biomet Biologics, Llc | Methods and non-immunogenic compositions for treating inflammatory disorders |
| CA2906356A1 (en) | 2013-03-15 | 2014-09-18 | Novelogics Biotechnology, Inc. | Antibodies to mica and micb proteins |
| EP3033617A4 (en) | 2013-08-12 | 2017-04-05 | Health Research, Inc. | Biomarkers for prostate cancer |
| WO2015081253A1 (en) | 2013-11-26 | 2015-06-04 | Biomet Biologics, Llc | Methods of mediating macrophage phenotypes |
| DK3086870T3 (en) * | 2013-12-27 | 2019-03-18 | Eliaz Therapeutics Inc | Plasmapheresis device |
| EP3097420A4 (en) * | 2014-01-24 | 2018-01-17 | Ntercept, LLC | Methods and compositions for immune dis-inhibition |
| CN106999550B (zh) * | 2014-10-03 | 2023-02-28 | 纳米提克斯有限责任公司 | 用于抑制可溶生物分子的生物活性的组合物以及方法 |
| US10441635B2 (en) | 2014-11-10 | 2019-10-15 | Biomet Biologics, Llc | Methods of treating pain using protein solutions |
| US9763800B2 (en) | 2015-03-18 | 2017-09-19 | Biomet C. V. | Implant configured for hammertoe and small bone fixation |
| EP3274010B1 (en) * | 2015-03-27 | 2019-10-02 | Eliaz Therapeutics, Inc. | Patient selective apheresis |
| CN104815360A (zh) * | 2015-04-14 | 2015-08-05 | 复旦大学 | 循环肿瘤细胞过滤治疗仪 |
| US10555675B2 (en) | 2015-05-15 | 2020-02-11 | Gauss Surgical, Inc. | Method for projecting blood loss of a patient during a surgery |
| US10789710B2 (en) | 2015-05-15 | 2020-09-29 | Gauss Surgical, Inc. | Methods and systems for characterizing fluids from a patient |
| WO2016187071A1 (en) | 2015-05-15 | 2016-11-24 | Gauss Surgical, Inc. | Systems and methods for assessing fluids from a patient |
| CN108135850A (zh) | 2015-07-29 | 2018-06-08 | 纳米提克斯有限责任公司 | 用于清除可溶性生物分子的模块化组合物及其相关方法 |
| US20190135929A1 (en) | 2015-08-28 | 2019-05-09 | The General Hospital Corporation | Agonistic anti-tumor necrosis factor receptor 2 antibodies |
| WO2017083525A1 (en) * | 2015-11-11 | 2017-05-18 | Opi Vi- Ip Holdco Llc | Composition and methods for anti-tnfr2 antibodies |
| JP6934253B2 (ja) | 2015-12-23 | 2021-09-15 | ガウス サージカル, インコーポレイテッドGauss Surgical, Inc. | 外科織物内の血液構成要素の量の評価方法 |
| EP3393539B1 (en) | 2015-12-23 | 2023-12-27 | Gauss Surgical, Inc. | System and method for estimating an amount of a blood component in a volume of fluid |
| DE102016106510A1 (de) * | 2016-04-08 | 2017-10-12 | ToposNomos Ltd. | Verfahren und Vorrichtung zum extrakorporalen Entfernen von pathogenen und/oder überzähligen Bestandteilen aus einer Zellprobe eines Patienten |
| JP2020502042A (ja) | 2016-10-19 | 2020-01-23 | ノヴェロジックス・バイオテクノロジー，インコーポレーテッド | Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体 |
| EP3563343A4 (en) | 2017-01-02 | 2020-08-19 | Gauss Surgical, Inc. | SURGICAL ITEM FOLLOW-UP WITH DUAL ELEMENT IMAGING PREDICTION |
| US11065345B2 (en) | 2017-01-04 | 2021-07-20 | Nanotics, Llc | Methods for assembling scavenging particles |
| US11229368B2 (en) | 2017-01-13 | 2022-01-25 | Gauss Surgical, Inc. | Fluid loss estimation based on weight of medical items |
| US20190083531A1 (en) | 2017-09-13 | 2019-03-21 | Bavarian Immunology Association GmbH | Purified blood for use in cancer therapy |
| AU2019205316A1 (en) | 2018-01-05 | 2020-07-30 | Path Ex, Inc. | Device for the capture and removal of disease material from fluids |
| US20190247560A1 (en) * | 2018-02-13 | 2019-08-15 | Gambro Lundia Ab | Extracorporeal devices and methods of treating complement factor related diseases |
| US20210382035A1 (en) * | 2018-10-25 | 2021-12-09 | Tl Genomics Inc. | Pretreatment of blood for classifying blood cells using microchannel |
| CN113302205B (zh) * | 2018-11-15 | 2024-12-06 | 综合医院公司 | 激动性肿瘤坏死因子受体超家族多肽 |
| JP7459449B2 (ja) | 2019-04-26 | 2024-04-02 | 東レ株式会社 | 可溶性腫瘍壊死因子受容体の吸着材料 |
| AU2019444218A1 (en) * | 2019-05-07 | 2021-11-25 | Immunicom, Inc. | Increasing responses to checkpoint inhibitors by extracorporeal apheresis |
| WO2021203144A1 (en) * | 2020-04-02 | 2021-10-07 | Nuwellis, Inc. | Multi-stage blood filtration |
| BR112023026577A2 (pt) | 2021-06-17 | 2024-03-05 | Immunicom Inc | Tnf modificado como um ligante de captura |
| CN116492991B (zh) * | 2023-04-20 | 2024-02-23 | 江苏恰瑞生物科技有限公司 | 可清除血液中TNF-α的血液灌流器填料制备方法 |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5677132A (en) * | 1971-05-20 | 1997-10-14 | Strahilevitz; Meir | Immunological assay reagent package |
| US4375414A (en) * | 1971-05-20 | 1983-03-01 | Meir Strahilevitz | Immunological methods for removing species from the blood circulatory system and devices therefor |
| US4189470A (en) * | 1973-01-30 | 1980-02-19 | Bio-Response, Inc. | Method for the continuous removal of a specific antibody from the lymph fluid in animals and humans |
| US4116589A (en) * | 1977-04-15 | 1978-09-26 | Avco Corporation | Extracorporeal pulsatile blood pump comprised of side by side bladders |
| USRE31688E (en) * | 1977-09-23 | 1984-09-25 | Hemotherapy, Inc. | Method and apparatus for continuous plasmapheresis |
| US4191182A (en) * | 1977-09-23 | 1980-03-04 | Hemotherapy Inc. | Method and apparatus for continuous plasmaphersis |
| US4439332A (en) * | 1978-08-14 | 1984-03-27 | American Cyanamid Company | Stable emulsion copolymers of acrylamide and ammonium acrylate for use in enhanced oil recovery |
| US4350156A (en) * | 1980-05-29 | 1982-09-21 | Japan Foundation For Artificial Organs | Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid |
| US4605394A (en) * | 1982-12-03 | 1986-08-12 | Simon V. Skurkovich | Methods for the treatment of pathological conditions by removing interferon from the organism |
| US4362155A (en) * | 1981-03-24 | 1982-12-07 | Skurkovich Simon V | Method and apparatus for the treatment of autoimmune and allergic diseases |
| US4824432A (en) * | 1981-03-24 | 1989-04-25 | S.V.S. Laboratories, Inc. | Method for treating AIDS and other immune deficiencies and immune disorders |
| US4512763A (en) * | 1981-05-04 | 1985-04-23 | Gamma Medical Products, Inc. | Method and apparatus for selective removal of constituents of blood |
| US4664913A (en) * | 1982-05-24 | 1987-05-12 | Xoma Corporation | Method for treating plasma for transfusion |
| US4634417A (en) * | 1982-12-06 | 1987-01-06 | Georgetown University | Process for treatment of tumors and apparatus therefor |
| RU2076151C1 (ru) * | 1984-07-05 | 1997-03-27 | Генентек, Инк. | Способ получения фактора некроза опухоли, человеческий фактор некроза опухоли |
| US4614513A (en) * | 1984-08-13 | 1986-09-30 | Fred Hutchinson Cancer Research Center | Method and apparatus for treatment to remove immunoreactive substances from blood |
| US4708713A (en) * | 1984-11-16 | 1987-11-24 | Anisa Medical, Inc. | Method and system for removing immunosuppressive components from the blood of mammals |
| US4801449A (en) * | 1985-01-11 | 1989-01-31 | Imre Corporation | Method for treatment of Kaposi's sarcoma |
| US5037649A (en) * | 1985-01-11 | 1991-08-06 | Imre Corporation | Method for treatment of HIV-infected patients |
| US4863611A (en) * | 1987-04-30 | 1989-09-05 | Massachusetts Institute Of Technology | Extracorporeal reactors containing immobilized species |
| US4865841A (en) * | 1987-10-23 | 1989-09-12 | Imre Corporation | Methods and compositions for transient elimination of humoral immune antibodies |
| US5135919A (en) * | 1988-01-19 | 1992-08-04 | Children's Medical Center Corporation | Method and a pharmaceutical composition for the inhibition of angiogenesis |
| JPH07106219B2 (ja) * | 1988-08-02 | 1995-11-15 | 宇部興産株式会社 | インターロイキン２レセプターの除去装置およびそれを備えた血液体外循環装置 |
| US5078673A (en) * | 1988-11-14 | 1992-01-07 | Neorx Corporation | Selective removal of radiolabeled antibodies |
| US5147638A (en) * | 1988-12-30 | 1992-09-15 | Oklahoma Medical Research Foundation | Inhibition of tumor growth by blockade of the protein C system |
| US7264944B1 (en) * | 1989-04-21 | 2007-09-04 | Amgen Inc. | TNF receptors, TNF binding proteins and DNAs coding for them |
| US6232446B1 (en) * | 1989-05-18 | 2001-05-15 | Yeda Research And Development Co. Ltd. | TNF ligands |
| US5216128A (en) * | 1989-06-01 | 1993-06-01 | Yeda Research And Development Co., Ltd. | IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it |
| US5290807A (en) * | 1989-08-10 | 1994-03-01 | Children's Medical Center Corporation | Method for regressing angiogenesis using o-substituted fumagillol derivatives |
| US5395760A (en) * | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
| US5605690A (en) * | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| ATE236249T1 (de) * | 1989-09-12 | 2003-04-15 | Hoffmann La Roche | Tfn-bindende proteine |
| DE4006269A1 (de) * | 1990-02-28 | 1991-08-29 | Max Planck Gesellschaft | Antikoerper gegen den tumor-nekrosefaktor-rezeptor |
| US6432405B1 (en) * | 1991-03-15 | 2002-08-13 | Duke University | Method of inhibiting HIV infection with CD44 and anti-CD44 antibodies |
| AU666128B2 (en) * | 1991-08-23 | 1996-02-01 | Alberta Research Council Inc. | Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients |
| DE4331358A1 (de) * | 1992-10-12 | 1994-04-14 | Braun Melsungen Ag | Verfahren zur quantitativen selektiven Entfernung oder präparativen Gewinnung von Tumor-Nekrose-Faktor (TNF) oder/und Lipopolysacchariden (LPS) aus wäßrigen Flüssigkeiten |
| EP0673389A1 (en) * | 1992-11-19 | 1995-09-27 | Dana Farber Cancer Institute | Antibodies for gm-csf receptor and uses thereof |
| US5910252A (en) * | 1993-02-12 | 1999-06-08 | Cobe Laboratories, Inc. | Technique for extracorporeal treatment of blood |
| US5888511A (en) * | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
| US5626843A (en) * | 1993-02-26 | 1997-05-06 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS, by removel of interferons, TNFs and receptors therefor |
| US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| CA2156721C (en) * | 1993-03-16 | 1999-06-01 | Thomas B. Okarma | Removal of selected factors from whole blood or its components |
| US5437861A (en) * | 1993-03-16 | 1995-08-01 | Applied Immune Sciences, Inc. | Removal of selected factors from whole blood or its components; and prevention and treatment of septic shock syndrome |
| CA2119089A1 (en) * | 1993-03-29 | 1994-09-30 | David Banner | Tumor necrosis factor muteins |
| US5716981A (en) * | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
| US5753227A (en) * | 1993-07-23 | 1998-05-19 | Strahilevitz; Meir | Extracorporeal affinity adsorption methods for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases |
| IL110787A0 (en) * | 1993-08-27 | 1994-11-11 | Sandoz Ag | Biodegradable polymer, its preparation and pharmaceutical composition containing it |
| NZ275876A (en) * | 1993-11-12 | 1997-12-19 | Idv Operations Ireland Ltd | Pourer with an air passageway and a pouring passageway for each of two containers; a bottle comprising two separate containers and a jig to align the neck of adjacent containers |
| US5639725A (en) * | 1994-04-26 | 1997-06-17 | Children's Hospital Medical Center Corp. | Angiostatin protein |
| US5705615A (en) * | 1994-10-06 | 1998-01-06 | Beth Israel Deaconess Medical Center | Antibodies specific for HTm4 |
| CA2167138C (en) * | 1995-01-17 | 2000-10-31 | Keigo Arimoto | Splicing gauge |
| CA2167872C (en) * | 1995-01-27 | 2007-04-03 | Masaru Nakatani | Adsorbent for removing interleukins and tumor necrosis factor, and process for removing the same |
| US6428790B1 (en) * | 1995-04-27 | 2002-08-06 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use |
| US5763415A (en) * | 1995-08-03 | 1998-06-09 | John Hopkins University School Of Medicine | Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer |
| DE19538641C2 (de) * | 1995-10-05 | 2000-09-21 | Privates Inst Bioserv Gmbh | Patientenspezifische Immunadsorber für die extrakorporale Apherese und Verfahren für deren Herstellung |
| JP2002504831A (ja) * | 1995-11-15 | 2002-02-12 | バクスター・インターナショナル・インコーポレイテッド | 自己抗体の除去による心筋症の処置 |
| US5861483A (en) * | 1996-04-03 | 1999-01-19 | Pro-Neuron, Inc. | Inhibitor of stem cell proliferation and uses thereof |
| US6017527A (en) * | 1996-07-10 | 2000-01-25 | Immunex Corporation | Activated dendritic cells and methods for their activation |
| US5869047A (en) * | 1996-10-22 | 1999-02-09 | Blake Laboratories, Inc. | Methods for therapeutically treating immunocomprised persons |
| US6245038B1 (en) * | 1997-01-07 | 2001-06-12 | Helmut Borberg | Method for treatment of ophthalmological diseases |
| US6221614B1 (en) * | 1997-02-21 | 2001-04-24 | The Regents Of The University Of California | Removal of prions from blood, plasma and other liquids |
| US6197289B1 (en) * | 1997-07-01 | 2001-03-06 | Terumo Cardiovascular Systems Corporation | Removal of biologically active agents |
| US6620382B1 (en) * | 1998-05-22 | 2003-09-16 | Biopheresis Technologies, Llc. | Method and compositions for treatment of cancers |
| US8197430B1 (en) * | 1998-05-22 | 2012-06-12 | Biopheresis Technologies, Inc. | Method and system to remove cytokine inhibitor in patients |
| US6287516B1 (en) * | 1998-07-10 | 2001-09-11 | Immunocept, L.L.C. | Hemofiltration systems, methods, and devices used to treat inflammatory mediator related disease |
| WO2000012103A1 (en) * | 1998-08-31 | 2000-03-09 | Ambrus Julian L | Method for removal of hiv and other viruses from blood |
| WO2000023140A1 (en) * | 1998-10-16 | 2000-04-27 | Mission Medical, Inc. | Blood processing system |
| AU1712700A (en) * | 1998-11-18 | 2000-06-05 | G.D. Searle & Co. | Restoration of platelet aggregation by antibody administration after gpiib/iiia antagonist treatment |
| US20010010818A1 (en) * | 1998-12-09 | 2001-08-02 | Engle Steven B. | Methods and formulations for reducing circulating antibodies |
| WO2000038760A2 (en) * | 1998-12-29 | 2000-07-06 | Occulogix Corporation | Rheological treatment methods and related apheresis systems |
| US6982089B2 (en) * | 1999-02-24 | 2006-01-03 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
| DE60031966T2 (de) * | 1999-04-23 | 2007-09-13 | Renamed Biologics, Inc. | Extrakorporaler kreislauf |
| US6774102B1 (en) * | 1999-09-29 | 2004-08-10 | Gambro Dialysatoren Gmbh & Co. Kg | Extracorporeal endotoxin removal method |
| EP1227843B1 (en) * | 1999-11-10 | 2009-10-14 | BioPheresis Technologies, Inc. | Method and system to remove cytokine inhibitor in patients |
| US6379708B1 (en) * | 1999-11-20 | 2002-04-30 | Cytologic, Llc | Method for enhancing immune responses in mammals |
| US6890315B1 (en) * | 2000-05-23 | 2005-05-10 | Chf Solutions, Inc. | Method and apparatus for vein fluid removal in heart failure |
| US7285105B2 (en) * | 2000-06-15 | 2007-10-23 | Jms Co., Ltd | Automatic dialyzer and dialyzing method |
| AUPQ846900A0 (en) * | 2000-06-29 | 2000-07-27 | Aruba International Pty Ltd | A vaccine |
| US20030148404A1 (en) * | 2000-07-27 | 2003-08-07 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders |
| US20020058031A1 (en) * | 2000-09-19 | 2002-05-16 | Tung Hsiaoho Edward | Methods for preparing diagnostic reagents using antibody preparation |
| US20020107469A1 (en) * | 2000-11-03 | 2002-08-08 | Charles Bolan | Apheresis methods and devices |
| US20020086276A1 (en) * | 2000-12-28 | 2002-07-04 | Srivastava Pramod K. | Immunotherapeutic methods for extracorporeal modulation of CD36 and its ligands |
| US6761700B2 (en) * | 2001-02-09 | 2004-07-13 | Orqis Medical Corporation | Extra-corporeal vascular conduit |
| US20020114728A1 (en) * | 2001-02-13 | 2002-08-22 | Kulish Victor V. | Electronic Sterilizer |
| US6878127B2 (en) * | 2001-04-10 | 2005-04-12 | Renaltech International, Llc | Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood |
| US6607501B2 (en) * | 2001-05-14 | 2003-08-19 | Reynolds G. Gorsuch | Process and apparatus for utilization of in vivo extracted plasma with tissue engineering devices, bioreactors, artificial organs, and cell therapy applications |
| US6685664B2 (en) * | 2001-06-08 | 2004-02-03 | Chf Solutions, Inc. | Method and apparatus for ultrafiltration utilizing a long peripheral access venous cannula for blood withdrawal |
| US7355017B2 (en) * | 2001-07-20 | 2008-04-08 | Absorber Ab | Blood group antigen fusion polypeptides and methods of use thereof |
| DE10144252A1 (de) * | 2001-08-31 | 2003-03-27 | Fraunhofer Ges Forschung | Nanopartikel mit daran immobilisiertem biologisch aktivem TNF |
| EP1434571B1 (en) * | 2001-10-05 | 2005-05-11 | SurModics, Inc. | Particle immobilized coatings and uses thereof |
| RU2218186C2 (ru) * | 2002-02-11 | 2003-12-10 | Ростовский научно-исследовательский онкологический институт | Способ лечения неоперабельного рака с метастазами в лимфоузлы |
| EP1949915B1 (en) * | 2004-04-30 | 2012-08-22 | BioPheresis Technologies, Inc. | Method and system to remove soluble TNFR1, TNFR2, and IL2R in patients |
| US20070065514A1 (en) * | 2005-09-22 | 2007-03-22 | Howell Mark D | Method for enhancing immune responses in mammals |
| US20080075690A1 (en) * | 2006-09-22 | 2008-03-27 | Mark Douglas Howell | Method for enhancing immune responses in mammals |
-
2005
- 2005-04-29 EP EP08007944A patent/EP1949915B1/en not_active Expired - Lifetime
- 2005-04-29 AU AU2005240082A patent/AU2005240082B2/en not_active Ceased
- 2005-04-29 CN CN2005800220636A patent/CN1980696B/zh not_active Expired - Fee Related
- 2005-04-29 EP EP05744057A patent/EP1740209A2/en not_active Ceased
- 2005-04-29 DK DK08007944.5T patent/DK1949915T3/da active
- 2005-04-29 US US11/119,214 patent/US20050265996A1/en not_active Abandoned
- 2005-04-29 WO PCT/US2005/015037 patent/WO2005107802A2/en active Application Filing
- 2005-04-29 CA CA2565215A patent/CA2565215C/en not_active Expired - Fee Related
- 2005-04-29 JP JP2007511060A patent/JP2008511340A/ja active Pending
- 2005-04-29 ES ES08007944T patent/ES2393637T3/es not_active Expired - Lifetime
- 2005-04-29 SI SI200531626T patent/SI1949915T1/sl unknown
- 2005-04-29 PT PT08007944T patent/PT1949915E/pt unknown
- 2005-04-29 PL PL08007944T patent/PL1949915T3/pl unknown
- 2005-04-29 RU RU2006142328/14A patent/RU2378016C2/ru not_active IP Right Cessation
-
2006
- 2006-10-24 IL IL178845A patent/IL178845A/en active IP Right Grant
-
2007
- 2007-10-30 US US11/929,540 patent/US20080145333A1/en not_active Abandoned
-
2009
- 2009-10-20 AU AU2009227872A patent/AU2009227872B2/en not_active Ceased
- 2009-11-02 IL IL201888A patent/IL201888A/en active IP Right Grant
- 2009-11-13 IN IN7374DEN2009 patent/IN2009DN07374A/en unknown
-
2010
- 2010-08-11 US US12/854,385 patent/US20110129441A1/en not_active Abandoned
-
2012
- 2012-05-22 US US13/477,805 patent/US20120328562A1/en not_active Abandoned
- 2012-11-14 CY CY20121101098T patent/CY1113345T1/el unknown
-
2013
- 2013-05-15 US US13/894,963 patent/US20130251672A1/en not_active Abandoned
-
2014
- 2014-09-26 US US14/498,749 patent/US20150231233A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2565215C (en) | Method and system to remove soluble tnfr1, tnfr2, and il2 in patients | |
| US8133490B2 (en) | Method and system to remove cytokine inhibitors in patients | |
| JP3694757B2 (ja) | 癌の処置のためのシステムおよびキット | |
| JP2006249112A (ja) | 患者中のサイトカインインヒビターを除去するための方法およびシステム | |
| HK1125026B (en) | Method and system to remove soluble tnfr1, tnfr2, and il2r in patients | |
| US20190083531A1 (en) | Purified blood for use in cancer therapy | |
| JPH01135725A (ja) | 抗−ｐＨ不安定アルフアインターフエロン抗体の製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20170501 |